AMD AI: Growth Trajectory Meets China Hurdles
AMD's Q3 revenue outlook is strong, but China AI chip sales face uncertainty as licenses are under review.

AMD's Q3 revenue outlook is strong, but China AI chip sales face uncertainty as licenses are under review.
Texas Instruments' sales slowed post-April, partly due to tariff pull-ins, sparking investor fears of a "mirage" turnaround. The CFO hinted at softer sales next year, potentially leading to production cuts, while analysts noted a cautious tone from the CEO. The market anticipates guidance cuts.
The FDA extended PYRUKYND's review for thalassemia by 3 months to Dec 7, 2025, after Agios submitted a plan (REMS) to manage liver injury risk. This oral medicine aims to treat adult alpha- or beta-thalassemia.
Anaphylm, Aquestive's needle-free sublingual epinephrine film for severe allergic reactions, is on track for FDA approval by Jan 31, 2026. It offers a device-free, orally delivered alternative to overcome needle fear.